Nervous Disorder TRIZ Cases

Oleanane-24-ester compounds modulate adhesion proteins, resolving the contradiction between therapeutic reliability and cancer invasion.

Formula 1 carbamates reduce spike-and-wave discharge frequency, overcoming existing drug limitations that exacerbate absence epilepsy.

Trimeric H-NOX assemblies overcome short circulation half-lives to deliver oxygen to hypoxic brain cancer zones.

Maleimidobutyric acid N-hydroxysuccinimide ester crosslinks CysAβ(33-40) peptides to keyhole limpet hemocyanin transport proteins.

Arsenic trioxide inhibits IL-6 production by T-lymphocytes, delaying the onset of secondary progressive multiple sclerosis.

Antibodies targeting the Na v 1.7 extracellular loop reduce current amplitude, resolving side effects from non-selective chemical inhibitors.

New compounds inhibit KDM1A enzyme activity to alter histone methylation states and restore normal cellular function.

Polymeric perfluorocarbon nanoemulsions use phase-changing cores to uncage drugs via ultrasound, resolving embolism risks from larger particles.

PAN-811 thiosemicarbazones neutralize oxidative stress and excitotoxicity to prevent chemotherapy-induced peripheral neuropathy without drug side effects.

An adeno-associated vector co-expresses TH and GCH1 enzymes to maintain continuous dopamine levels, resolving dyskinesia caused by intermittent L-DOPA delivery.

Tripeptides containing redox active amino acids scavenge radicals to inhibit peroxidase activity.

A pharmaceutical composition combines high-dose acetylcholinesterase inhibitors with peripheral anticholinergics to elevate plasma concentrations.

Defined culture medium inhibiting BMP and TGF pathways yields reproducible neural precursors without sorting.

Anti-EMP2 antibodies deplete resistant cancer stem cell populations, preventing tumor recurrence after bulk elimination.

Chimeric antibodies sequester cocaine in plasma, lowering brain concentrations and reducing immune response.

Site-directed mutagenesis replaces surface cysteine residues with serine to stabilize the enzyme against proteolytic degradation and reduce immunogenicity.

Microglia-modifying compounds address congenital cytomegalovirus by altering immune cell function during pregnancy, reducing postnatal neurological disorders.

A therapeutic laminate embeds superparamagnetic nanoparticles to generate internal heat via electromagnetic induction.

Co-administering bupropion with dextromethorphan inhibits CYP2D6 metabolism, increasing plasma levels and therapeutic efficacy while reducing adverse events.

NCKAP1 protein restores microglial phagocytic function via actin regulation, addressing ineffective neurodegenerative disease treatments.

Combining a selective 5-HT6 receptor antagonist with acetylcholinesterase inhibitors to improve cognitive function in dementia patients.

A fumaric acid salt of (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine exhibits high crystallinity and non-hygroscopicity.

Peptide inhibitors target the wedge domain of LAR phosphatases to reduce CSPG-mediated inhibition, enabling axon regeneration after spinal cord injury.

HVEM cis complexes bind BTLA and CD160 to inhibit T cell activation, resolving autoimmune response risks.

Monothioglycerol or thiocyanate salts reduce impurity formation while maintaining skin permeability.

Purifying cKit positive cardiac neural crest cells overcomes identification uncertainties to enable reliable differentiation into cardiomyocytes.

Tricyclic pyrone compounds restore mitochondrial dynamics and enhance bioenergetics in neuronal cells to delay neurodegenerative disease progression.

Adult neural stem cells migrate to inflamed central nervous system areas via chemokine receptors.

A targeted inhibitor molecule binds Annexin IV to block complement signaling during thrombolytic therapy.

Modified cyclic peptides neutralize toxic amyloid-beta oligomers, enabling early diagnosis before symptom onset.

Segmented antibody development resolves the trade-off between therapeutic efficacy and manufacturing complexity while targeting inflammatory disorders.

Enzymatic hydrolysis of whole soy milk with Bacillus polyfermenticus creates functional peptides that enhance motor ability without caffeine side effects.

Specifically targeting the PD-1 pathway, these fully human antibodies balance immune efficacy against tumors with reduced autoimmune risk.

Direct oligonucleotide administration eliminates vector safety concerns while selectively reducing aberrant transcripts through sequence complementarity.

Alkylresorcinol extracts normalize circadian rhythms via gene expression, avoiding side effects associated with endocrine hormone therapies.

Fucosyltransferase enzymes modify cell surface glycans to increase selectin binding affinity, resolving low stem cell homing efficiency in target tissues.

Concentrated brain-targeting antibodies with permeation enhancers overcome subcutaneous volume limits to improve cognitive function.

Transdermal cannabidiol delivery reduces gastrointestinal and liver side effects while improving clinical outcomes in fragile x syndrome.

Anti-CGRP antagonist antibody reduces visceral pain thresholds without central nervous system impairment.

Macrocyclic heterocycle derivatives activate orexin-2 receptors, restoring lost signaling to treat narcolepsy root causes.

Segmented polypeptides dimerize on dual-antigen cancer cells to eliminate tumors while sparing non-malignant tissue.

A chimeric protein combines a cell-specific targeting agent with Yersinia outer protein P to selectively destroy TNF-producing cells.

Intrathecal mesenchymal stromal cell suspension overcomes ineffective conventional agents by restoring cerebral glucose metabolism and cognitive function.

Modified naphthoquinone scaffolds improve seizure control while reducing side effects and adverse drug interactions found in current therapies.